OKYO Pharma Limited (OKYO)
OKYO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | OKYO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Guernsey |
| IPO year | 2022 |
| SEC CIK | 0001849296 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-07-20 |
| Cash and burn | $14.6M cash; operating cash flow -$1.5M a quarter. | Report 2026-03-31 |
| Shares outstanding | 52,479,527 (2026-07-15); 37,610,676 a year earlier; 25,553,274 three years earlier. | Cover page 2026-07-15 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-02-17 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PKF Littlejohn LLP, London, United Kingdom | PCAOB Form AP 2026-07-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $136K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | Not filed | -$8.9M | -$5.9M | $14.6M | No debt tags | Needs four quarters | 20-F 2026-07-20 |
| FY 2025 2025-03-31 | Not filed | -$4.7M | -$1.8M | $1.6M | $2.7M | Needs four quarters | 20-F 2025-07-18 |
| FY 2024 2024-03-31 | Not filed | -$16.8M | -$9.5M | $827K | No debt tags | Needs four quarters | 20-F 2025-07-18 |
| FY 2023 2023-03-31 | Not filed | -$13.3M | -$7.7M | $4.0M | No debt tags | Needs four quarters | 20-F 2025-07-18 |
| FY 2022 2022-03-31 | Not filed | -$5.4M | -$5.5M | $2.7M | No debt tags | Needs four quarters | 20-F 2024-08-13 |
| FY 2021 2021-03-31 | Not filed | -$3.4M | -$1.6M | $6.9M | No debt tags | Needs four quarters | 20-F 2023-08-15 |
| FY 2020 2020-03-31 | Not filed | -$1.5M | -$1.2M | $235K | No debt tags | Needs four quarters | 20-F 2022-08-15 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-17 |
| Latest annual report | 20-F | 2026-07-20 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 312 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.6% |
| 1 month | -6.1% |
| 3 months | -10.6% |
| Year to date | -34.8% |
| 1 year | -43.5% |
| From 52-week high | -56.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| GRML | Greenland Mines Ltd. | $3.50 | -3.05% | $51.9M |
| ELOX | Eloxx Pharmaceuticals Inc. | $12.75 | -3.04% | $51.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier